Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVS Health Corporation (“CVS” or the “Company”) (NYSE: CVS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVS Health Corporation - CVS

LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Announces A Probe Into Allegations Against CVS Health Corporation (CVS) And Calls For Investor Participation

Herbalife

Walgreens

Zacks Retail-Pharmacies and Drug Stores industry players like WBA and HLF are likely to gain despite reimbursement challenges that are hurting the overall health of the industry. CVS might struggle in the face of economic challenges.

2 Stocks to Watch & One to Avoid From the Volatile Retail Pharmacy Industry

Given its better valuation, we believe Walgreens stock (NYSE: WBA) is a better pick than its peer CVS Health stock (NYSE: CVS). WBA stock trades at 0.1x revenues, versus 0.2x for CVS, given the latter's superior revenue growth, profitability, and financial position.

After A 40% Fall Is Walgreens Stock A Better Pick Over CVS Health?

LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Declares an Investigation into Accusations Against CVS Health Corporation and Advocates for Investor Engagement

Toyota Motor

Verizon

The stock market is near fresh new all-time highs. Traders continue to be excited about the possibilities of artificial intelligence, semiconductors and other such cutting-edge innovations.

Blue-Chip Behemoths: 3 Industry Giants Trading at Shockingly Low Prices

LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CVS IMPORTANT ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CVS Health Corporation and Encourages Investors to Contact the Firm

Boeing

Altria

Pfizer

AT&T

Tesla

Exxon Mobil

As you approach retirement, it's crucial to carefully consider your investment portfolio and make strategic decisions to safeguard your financial future. While some stocks may seem attractive, certain investments can pose significant risks to your retirement savings.

Retirement Roadblocks: 7 Stocks to Avoid as You Near the Finish Line

Agree Realty

Broadstone Net Lease

Essential Properties Realty Trust Inc

Gladstone Commercial

NETSTREIT Corp

Realty Income Corp

Alpine Income Property Trust

Vici Properties

W. P. Carey

There is significant mispricing among triple net REITs due to a lack of consideration for changing the tenant landscape. Net store openings indicate positive occupancy and rental rates, but some REITs are exposed to troubled areas. REITs with exposure to CVS and Walgreens may face challenges with lease expirations, requiring substantial capex and potential revenue disruption.

Triple Net REITs Mispriced As Tenancy Shifts

LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT ACTION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against CVS Health Corporation and Encourages Investors to Contact the Firm

Dollar General

Estee Lauder

Five Below

Southwest Airlines

Newell Brands

PayPal

The current market rally has been very disproportionate and has been dominated by Big Tech. Many top technology companies with the largest market capitalizations have made significant rebounds since mid-2022.

7 Deeply Discounted Stocks With 100%+ Upside Potential

LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT ACTION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against CVS Health Corporation and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CVS Health Corporation and Encourages Investors to Contact the Firm

CVS Health (CVS) reported earnings 30 days ago. What's next for the stock?

Why Is CVS Health (CVS) Up 1.6% Since Last Earnings Report?

NIKE

Starbucks

Starbucks stock has been struggling as consumer demand continues to stall. Nike's brand remains popular with teens, but sales have underwhelmed of late.

The S&P 500 Is at Record Levels but These 3 Stocks Are Still Near Their 52-Week Lows

CVS stock has plunged after reporting Q1 2024 results, presenting a potential buying opportunity due to its undervaluation. This stock now offers a 4.63% yield and CVS has built a unique ecosystem that makes it an attractive investment. Medicare Advantage presents a headwind for insurance companies in 2024, but this is a buying opportunity because it offers long-term growth potential.

CVS: Shares Decimated, But I'm Buying For The 4.6% Yield And Rebound Potential

LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against CVS Health Corporation and Encourages Investors to Contact the Firm

CVS Health Corporation (NYSE:CVS ) Bernstein's 40th Annual Strategic Decisions Conference May 29, 2024 10:00 AM ET Company Participants Karen Lynch - President and CEO Tom Cowhey - Executive Vice President and Chief Financial Officer Conference Call Participants Lance Wilkes - Bernstein Lance Wilkes Okay. So we're going to kick-off.

CVS Health Corporation (CVS) Bernstein's 40th Annual Strategic Decisions Conference

Bank of America

Bank of Nova Scotia

Enbridge

ING Groep NV

JPMorgan Chase & Co

Coca-Cola

PepsiCo

Telefonica SA

The inclusion of high dividend yield companies is important when building a dividend portfolio that aims to generate a passive and sustainable income stream. You should carefully select your high dividend yield companies and set allocation limits for companies with higher probabilities of dividend reduction. With this strategy, you decrease the risk level of your investment portfolio while enhancing the chances of positive investment outcomes.

Yields Of More Than 9%: My Top 10 High Dividend Yield Companies For June 2024

CVS Health (NYSE: CVS) saw its net income expand by $4.2 billion or 101% y-o-y to $8.3 billion in 2023. This can primarily be attributed to the opioid litigation charges included in the 2022 results.

How Are CVS Health's Profit Margins Trending?

Miami, Florida--(Newsfile Corp. - May 28, 2024) - It's Bigger Than Us (IBTU), a 501(c)(3) nonprofit dedicated to advancing health equity and addressing social determinants of health, proudly announces a Community Health and Resource event in collaboration with Aetna, a CVS Health Company. This transformative event is scheduled for June 23, 2024, at Notre Dame d'Haiti Catholic Church, aiming to uplift the Miami community by providing essential health resources and support.

Community Health and Resource Event in Miami: IBTU and Aetna CVS Health Unite for Health Equity

Bionano Genomics

Teladoc

Healthcare stocks often hold significant potential due to the constant demand for medical advancements. However, not all companies in this sector are poised for growth.

3 Sorry Healthcare Stocks to Sell in May While You Still Can

Walmart

CVS, Walmart, and Walgreens are all scaling back or shuttering retail health clinics.  Walgreens' VillageMD recorded a $6 billion loss, an example of just how difficult it has become to generate profits from a health-care model that retailers over the past decade bet would be a big win.

Why Walmart, Walgreens, CVS retail health clinic experiment is struggling

Gilead Sciences

CVS Health provides a comprehensive suite of interrelated healthcare services. Gilead Sciences' sales are growing steadily, and newer approvals should help.

2 Beaten-Down Dividend Stocks to Buy and Hold For 10 Years

CVS Health Corp's share price has fallen, presenting an attractive entry opportunity with a current dividend yield of 4.8%. The risk profile includes slashed guidance and increased costs, but these issues are not unique to CVS and may be temporary. CVS has shown consistent dividend growth over time and has a potential upside of 28.5% based on average Wall St. price targets.

News for CVS Health Stock (CVS)